Healthcare | April 28, 2026
Rheumatology Awareness Walkathon 2026 spotlights arthritis and autoimmune care
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Subscribe To Our Newsletter & Stay Updated
